PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33929970-4	2021	Bleomycin-induced pulmonary fibrosis in mice exhibited that AOBEE improved forced vital capacity (FVC) and alveolar structure and inhibited alpha-SMA, vimentin, and collagen expression.	Bleomycin	0-9	vimentin	Mus musculus	151-159	
31775746-13	2019	By contrast, vimentin and alpha-SMA, two EMT markers, were upregulated in the lungs of BLM-treated mice.	Bleomycin	87-90	vimentin	Mus musculus	13-21	
25762200-3	2015	We demonstrate that central pathophysiologic events in ALI (inflammation, IL-1beta levels, endothelial and alveolar epithelial barrier permeability, remodelling and fibrosis) are attenuated in the lungs of Vim(-/-) mice challenged with LPS, bleomycin and asbestos.	Bleomycin	241-250	vimentin	Mus musculus	206-209	
25762200-4	2015	Bone marrow chimeric mice lacking vimentin have reduced IL-1beta levels and attenuated lung injury and fibrosis following bleomycin exposure.	Bleomycin	122-131	vimentin	Mus musculus	34-42	
24726524-8	2014	Immunofluorescent staining indicated vimentin-positive epithelial cells frequently occurring in the thickened epidermis of BLM-treated mice.	Bleomycin	123-126	vimentin	Mus musculus	37-45	
21984393-3	2012	On days 17-21 following intratracheal bleomycin administration, ~4% of GFP-positive epithelial-derived cells expressed vimentin or alpha-smooth muscle actin (alpha-SMA).	Bleomycin	38-47	vimentin	Mus musculus	119-127	
21596473-8	2011	When the ATII-like cells were exposed to either bleomycin or a TGF(b1)-EGF cocktail, they underwent phenotypic changes including acquisition of a mesenchymal/fibroblastic morphology, upregulation of mesenchymal markers (Col1, Vim, a-Sma, and S100A4), and downregulation of surfactant proteins and E-cadherin.	Bleomycin	48-57	vimentin	Mus musculus	226-229